Drug, across the briefings
Imetelstat across 14 cancers
Imetelstat appears in 14 of the briefings; its FDA label names 1 of those diseases.
| Disease | FDA label | Open Targets stage, on which gene | Trials | Active |
|---|---|---|---|---|
| Myelodysplastic syndromes | label names disease | — | — | |
| Anal cancer | approved on TERT | — | — | |
| Bladder cancer | approved on TERT | — | — | |
| Cervical cancer | approved on TERT | — | — | |
| Glioblastoma | approved on TERT | 2 | 0 | |
| Head and neck cancer | approved on TERT | — | — | |
| Hepatocellular carcinoma | approved on TERT | — | — | |
| Lower-grade glioma | approved on TERT | — | — | |
| Melanoma | approved on TERT | — | — | |
| Neuroblastoma | approved on TERT | 2 | 0 | |
| Soft tissue sarcoma | approved on TERT | 1 | 0 | |
| Testicular cancer | approved on TERT | — | — | |
| Thyroid cancer | approved on TERT | 1 | 0 | |
| Vulvar cancer | approved on TERT | — | — |
The label column is the briefing's openFDA stage: a label whose Indications and Usage names the disease. The Open Targets column is the furthest clinical stage recorded for the drug against any gene on that briefing's target list, in any indication. Trials are ClinicalTrials.gov interventional studies naming the drug and the disease, from the briefing's trials stage; a dash means the briefing did not search this drug in that disease (it searches the drugs Open Targets lists against its own genes), which is not the same as none. Salt forms, biosimilar suffixes and formulation words are merged by the same rule the briefings use.